Biotech News

Viracta Therapeutics Announces Wind Down of Operations

Viracta Therapeutics (VIRX)Viracta Therapeutics2026-06-25 13:46 ESTCompany update

VIRX (VIRX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is virx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

VIRXViracta Therapeutics2026-06-25 13:46 EST

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

VIRXViracta Therapeutics2026-06-25 13:46 EST

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

VIRXViracta Therapeutics2026-06-25 13:46 EST

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VIRXViracta Therapeutics2026-06-25 13:46 EST

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

NRSNNeuroSense Therapeutics2026-06-25 13:46 EST

NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease

JAGXJaguar Health2026-06-25 13:46 EST

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

MKTMaia Biotechnology2026-06-25 13:46 EST

MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer

CADLCandel Therapeutics2026-06-25 13:46 EST

Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

ICCMIceCure Medical2026-06-25 13:46 EST

IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement

LYELLyell Immunopharma2026-06-25 13:46 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

View all latest news

Viracta Therapeutics

Viracta Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

VIRXViracta Therapeutics2026-06-26 08:50 EST

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

VIRXViracta Therapeutics2026-06-26 08:50 EST

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

VIRXViracta Therapeutics2026-06-26 08:50 EST

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

VIRXViracta Therapeutics2026-06-26 08:50 EST

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

VIRXViracta Therapeutics2026-06-26 08:50 EST

Viracta Therapeutics Announces Wind Down of Operations

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States